标准化屋尘螨变应原制剂治疗儿童变应性哮喘68例  

Standardized mites allergens immunotherapy for allergic asthma in 68 children

作　　者：王模奎[1] 黄英[1] 刘恩梅[1] 戴继宏[1] 陈坤华[1] 蒋永惠[1] 李素碧[1] 

机构地区：[1]重庆医科大学附属儿童医院呼吸科,重庆400014

出　　处：《中国新药与临床杂志》2006年第12期935-938,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的:观察标准化屋尘螨变应原制剂治疗儿童变应性哮喘前后的临床疗效、肺功能与不良反应。方法:68例轻-中度儿童哮喘给予标准化屋尘螨变应原制剂治疗共25 wk。治疗前后监测肺功能,每日晨、晚间PEF,日间、夜间症状和药物评分。记录每次注射后的不良反应。结果:治疗前后FEV1,PEF占预计值的百分比分别为(96±s 24,113±16),(92±23,116±16)。0～12 wk和13～25 wk的平均日间、夜间症状和药物评分分别为(0．13±0．10,0．06±0．06),(0．06±0．07,0．02±0．04),(0．507±0．023, 0．48±0．05)分。差异均有显著意义(P<0．05)。每日晨、晚间PEF变异率从wk 13起即有变小趋势,但较0～12 wk时无显著差异(P>0．05)。未发生严重不良事件。结论:标准化屋尘螨变应原制剂治疗儿童变应性哮喘25 wk能显著减轻病人的症状、减少用药量和改善肺通气功能,可安全用于治疗儿童变应性哮喘。AIM： To observe the clinical effects, lung function, and adverse reactions of standardized mites allergens immunotherapy for allergic asthmatic children. METHODS： Sixty-eight children with mild to moderate allergic asthma were immunotherapy with standardized mites allergens for 25 wk. Master Scope children＇s spirometry was used for monitoring lung function assessment of asthmatic children pre- and post-treatment. Moreover, morning and night peak expiratory flow （PEF）, scores of inter-day and inter-night symptoms and medications were observed. Adverse reactions were recorded ＂after every injection. RESULTS： The predicted percentages of FEV1, PEF before and after immunotherapy were （96 ~ s 24, 113 ± 16）, （92 ± 23, 116 - 16） respectively. The average scores of inter-day and inter-night symptom and medications during 0 - 12 wk and 13 - 25 wk periods were （0.13 ± 0.10, 0.06 ± 0.06）, （0.06 ± 0.07, 0.02 ± 0.04）, （0.507 ± 0.023, 0.48 ±0.05） respectively. After the comparison, all parameters improved significantly （P 〈 0.05）. Although a shrinking tendency has been noticed from the mean morning and night PEF variability after 13 wk, there was no statistical significance after comparing with those of 0 - 12 wk （P 〉 0.05）. No severe adverse reaction occurred. CONCLUSION： Standardized mites allergens immunotherapy 25 wk for mild to moderate allergy asthmatic children with obvious relief of clinical symptoms, reduction of medication dosage and improve lung function.

关 键 词：儿童 哮喘 免疫疗法 标准化屋尘螨变应原制剂 

分 类 号：R974.3[医药卫生—药品] R562.25[医药卫生—药学]